Details
Category: Volume 07 Issue 11 November 2019
Hits: 1267

Title: Sleep Disorders in Parkinson’s Disease

Authors: Ridha Bushra, Juveria Tarannum, D. Sudheer Kumar, P. Kishore

 DOI: https://dx.doi.org/10.18535/jmscr/v7i11.24

Abstract

Sleep disturbances are common problems affecting the quality life of Parkinson's disease (PD) patients and worsen their symptoms. Impaired sleep can have a severe impact on health, general well being. Sleep disturbances includes various causes such as nocturnal motor disturbances, depressive symptoms, and medication use. Co-morbidity of PD with sleep apnoea syndrome, restless legs syndrome, rapid eye movement sleep behaviour disorder, or circadian cycle disruption also results in impaired sleep. Sleep disorders in PD may occur during the day or at night and which can be before or during the disease. Patients with PD should be asked about their symptoms related to sleep disturbances. Treatment strategies should be based on physical examinations which need to be tailored to the individual and reviewed regularly.

References

  1. Dursunaygun, sleep disorders in Parkinson’s disease– understanding pathophysiology and developing therapeutics strategies 2018, doi:10.5772
  2. Brockmann k, Gasser T. Genetics of Parkinson’s disease, In Jankovic J, Tolosa E, editors, Parkinson’s disease and movement disorders, Philadelphia; Wolterskluwer; 2015. pp.65-74.
  3. Santamaria J. Sleep and fatigue in Parkinson’s disease. In Jankovic J, Tolosa E, editors, Parkinson’s disease and movement disorders, Philadelphia; Wolterskluwer; 2015. pp.428-439.
  4. Yun shen and C hunfenglin, sleep disorders in Parkinson’s disease present status and future prospects chin med J, 2018 apr 20;131(8):883-885.
  5. Isobel T. French and Kalai A. Muthuswamy KA (2016) A review of sleep and its disorders in patients with Parkinson’s disease in relation to various brain structures. Front aging neurosci.8:114.doi.10.3389.
  6. Aston Jones, G Chen, Zhu y and Oshinsky, M.L (2001) A neural circuit for circardian regulation of arousal. Nat. neurosci, doi-10.1038/89522,4,732-738.
  7. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JC. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine, chemical practice guideline J clin sleep med 2017;13(2).
  8. Zhu k, Van hilten JJ, Marinus J. The course of insomnia in Parkinson’s disease. Parkinsonism and related disorders. 2016;33:51-57.
  9. Joseph T dipiro, Robert L.Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey, Pharmacotherapy A pathophysiologic approach, 7th edition pp1193-1195.
  10. Neylan TC, Reynolds CF, Kupfer DJ. Sleep disorders. In:Yudofsky SC, Hales RE, eds. American Psychiatric press textbook of neuropsychiatry, 3rd edition Washington, DC: American psychiatric press 2000:583-606.
  11. Peppard PE, Szklo-coxem, Hla KM, Young T .Longitudinal association of sleep related breathing disorder and depres Arch intern med 2006;166:1709-1715.
  12. Kevin K motamedi, BS, Andrew C mcclary,SCB and Ronald G amedee, obstructive sleep apnea ,a growing problem .Ochsner J.2009 fall; 9(3):149-153.
  13. Lucia spicuzza, Daniela Caruso and Giuseppe Di maria, OSA syndrome and its management, doi:10.1177/2040622315590318
  14. Grunstein RR , hedner J ,Grotel L. Treatment options for sleep apnea .drugs 2001;61:237-251.
  15. Giuseppe loddo, Giovanna calandra–buonaura, Luisasambafi ,Giulia giamini, Annagraziacecere, Pietrocortelli and Federica provini, The treatment of sleep disorder in parkinsons disease : from research to clinical practice , front.neurol 8:42,doi:10.3389.
  16. Arnulf I.(2005) Excessive daytime sleepiness in parkinsonism .Sleep med.Rev.9,185 -200.doi:10.1016
  17. Claassen DO, Kutscher SJ. Sleep disturbances in parkinsons disease patients and management options .nature and science of sleep.2011;(3):125-133
  18. Christian guilleminault , Stephen N brooks, Excessive daytime sleepiness ,A challenge for practising neurologist ,brain, volume. 124, issue 8,aug 2001,pg.1482-1491.
  19. Symonds CP nocturnal myoclonus. Jneurolneurosurg psychiatry,1953 Aug ;16 (3):166-171.
  20. Silber MH ,Becker PM, Earley C ,et al .Willis –Ekborn disease foundation revised consensus statement on the management of RLS. Mayoclinproc 2013;88:977
  21. Montplaisir J, Boucher S, Poirier G et al (1957) clinical, polysomnographic and genetic characteristic of RLS: a study of 133 patients diagnosed with new standard criteria..movement disorder 12:61-65
  22. Sasai T, Matsuura M, Invoc Y. Factors associated with the effect of pramipazole on symptoms of rapid eye movement sleep behavior disorder. Parkinsonism related sleep disorder 2013;19:153
  23. De oliveriaco, et al. Opioids for restless legs syndrome ,2016,doi 10.1002/14651858.CD006941.
  24. Andrew Kornberg, Simon Harvey ,Mark mackay and Wirginiamaixner. chapter 33:neurologic conditions. In:paediatric handbook 8th edition,2009 march ,doi:10.10032?9781444308051.ch33.
  25. EG Harrison et al. disabil rehabil. Epub 2018, march 21. Non pharmacologic interventions for restless legs syndrome :a systematic review of randomised controlled trials.2019aug, 41(17):2006-2014. doi.10.1080/09638288.2018.1453875
  26. Jackie bhattarai and scottsumerall, A review on current and future treatment options for narcolepsy : sleep sci.2017 jan –mar;10(1);19-27,doi :10.5935/1984-0063.20170004.
  27. Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo, harrisons principle of internal medicine,19th edition pg 180-189.
  28. Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo, harrisons principle of internal medicine,19th edition pg 189-191.
  29. Weaver Te, Cuellar N. A randomized trial evaluating the effectiveness of the sodium oxybate in narcolepsy. Sleep.2006;29: 11891194.
  30. Parkes, S. Chen, S. Clift, Mdahlitz the clinical diagnosis of Narcoleptic syndrome, October 2008, volume 7, doi:10.1046/j.1365-2869.1998.00093.x.
  31. Mchel Billard, Narcolepsy: Current treatment options and future approaches, 2008 june, 4(3) pg 557-566.
  32. Bradley F. Boeve REM sleep behaviour disorder updated review of the core features, jan 2011, doi:10.1111/j.1749-6632.2009.05115.x
  33. Sforza E, Kriger J, Petiau C. REM sleep behaviour disorder-clinical and physiopathological findings. Sleep med rev1997;1:57.
  34. Howell MJ, Arneson PA, Schnenck CH. A. Novel therapy for RBD. J. Clin sleep med 2011;7:639.
  35. MC Grane, Leung JG, st. Louis EK, Boeve BF, Melatonin therapy for RBD: A critical review of evidence. Sleep med 2015,16:19.
  36. SSRIs information. USFDA. August 19, 2019.
  37. Giacopo R, Fasano A, Quaranta D, et al. rivastigmine as alternative treatment for refractory RBD in Parkinson’s disease. Movement disorder 2012, 27:559.
  38. Semba K, Aminergic and Cholinergic afferents to REM sleep induction regions of the pontine reticular formation. Neural. 330,543-546,doi10.1002/cne.903300410.
  39. Arnald, Antelmi E, St. Louis EK, et al. Idiopathic RBD and neuro degenerative risk: to tell or not to the patient? How to minimize the risk? Sleep med rev2017;36:82.
  40. Joseph T dipiro, Robert L.Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey, Pharmacotherapy A pathophysiologic approach, 7th edition pp1191-1199.

Corresponding Author

Dr P. Kishore

Head, Department of Pharmacy Practice,Care College of Pharmacy, Oglapur (v), Damera (m), Warangal rural, Telangana, India, 506006